Camptosar

Colorectal Carcinoma, Neoplasm Metastasis, Rhabdomyosarcoma + 8 more
Treatment
4 FDA approvals
20 Active Studies for Camptosar

What is Camptosar

IrinotecanThe Generic name of this drug
Treatment SummaryIrinotecan is a medication used to treat colorectal cancer. It works by blocking an enzyme called topoisomerase I, which stops the DNA strand from rejoining and causes cell death. It is derived from camptothecin and was approved for advanced pancreatic cancer in 2015. The brand name for the drug is Onivyde.
Camptosaris the brand name
image of different drug pills on a surface
Camptosar Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Camptosar
Irinotecan
1996
56

Approved as Treatment by the FDA

Irinotecan, commonly known as Camptosar, is approved by the FDA for 4 uses which include Metastatic Colorectal Carcinoma and refractory, metastatic Pancreatic adenocarcinoma .
Metastatic Colorectal Carcinoma
Used to treat Metastatic Colorectal Carcinoma in combination with Fluorouracil
refractory, metastatic Pancreatic adenocarcinoma
Used to treat refractory, metastatic Pancreatic adenocarcinoma in combination with Fluorouracil
Colorectal Neoplasms
Used to treat Metastatic Colorectal Carcinoma in combination with Fluorouracil
Neoplasm Metastasis
Used to treat refractory, metastatic Pancreatic adenocarcinoma in combination with Fluorouracil

Effectiveness

How Camptosar Affects PatientsIrinotecan is a medicine used to treat colorectal cancer. It works by preventing the formation of a chemical bond between two enzymes in the cell nucleus, which helps to regulate DNA replication, recombination, and repair. If the bond is not formed, DNA strands can't be rejoined and the cell can't survive. Irinotecan is specifically targeted to cells in the S-phase of the cell cycle, meaning it affects cells that are actively replicating. The exact role of its active metabolite, SN-38, is not known.
How Camptosar works in the bodyIrinotecan stops cells from reproducing by interfering with the DNA replication process. It does this by binding to a protein called topoisomerase I and preventing it from repairing the DNA strands that have been damaged. This results in the accumulation of double-stranded breaks in the DNA, leading to cell death.

When to interrupt dosage

The quantum of Camptosar is reliant on the diagnosed condition, for example Ovarian Cancer, Pancreatic Cancer and Stomach Cancer. The dosage fluctuates as per the technique of delivery (e.g. Injection, solution or Injection) specified in the table beneath.
Condition
Dosage
Administration
Colorectal Carcinoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Neoplasm Metastasis
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Rhabdomyosarcoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Ovarian Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Sarcoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Non-Small Cell Lung Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Small Cell Lung Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Stomach Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Colorectal Neoplasms
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Glioblastoma
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous
Pancreatic Cancer
, 20.0 mg/mL, 40.0 mg/mL, 100.0 mg/mL, 4.3 mg/mL, 43.0 mg, 50.0 mg/mL, 30.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Suspension, Suspension - Intravenous

Warnings

There are 20 known major drug interactions with Camptosar.
Common Camptosar Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Irinotecan is combined with Aldosterone.
Camptosar Toxicity & Overdose RiskThose taking Metformin may experience digestive issues, such as nausea, vomiting, stomach discomfort, diarrhea, and infection.
image of a doctor in a lab doing drug, clinical research

Camptosar Novel Uses: Which Conditions Have a Clinical Trial Featuring Camptosar?

At present, 1157 active studies are evaluating the effectiveness of Camptosar in treating Esophageal Cancer, Glioblastoma and Metastatic Colorectal Carcinoma.
Condition
Clinical Trials
Trial Phases
Ovarian Cancer
16 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Stomach Cancer
113 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
Pancreatic Cancer
188 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1
Neoplasm Metastasis
0 Actively Recruiting
Non-Small Cell Lung Cancer
314 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1
Rhabdomyosarcoma
0 Actively Recruiting
Colorectal Carcinoma
0 Actively Recruiting
Colorectal Neoplasms
0 Actively Recruiting
Sarcoma
51 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Small Cell Lung Cancer
45 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
Glioblastoma
61 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3

Camptosar Reviews: What are patients saying about Camptosar?

4Patient Review
2/22/2010
Camptosar for Cancer of Large Intestine
I experienced diarrhea four to five times a day, which made it difficult to leave the house. I also constantly had a nose drip and felt raw stomach sensations. However, after 3 months of treatment, new tumor growth disappeared.
4Patient Review
3/2/2010
Camptosar for Colon and Rectal Cancer that has Spread to Another Area
The stomach discomfort I experienced was manageable and didn't start until the last few months of treatment. The pre-medication really helped to cut down on the diarrhea.
3.3Patient Review
8/15/2009
Camptosar for Malignant Brain Tumor Glioblastoma
The side effects of this treatment were so bad that I lost 30 pounds and couldn't leave my house.
1.7Patient Review
2/3/2009
Camptosar for Colon and Rectal Cancer that has Spread to Another Area
I absolutely detest this medication.
1Patient Review
10/20/2007
Camptosar for Colon and Rectal Cancer that has Spread to Another Area
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about camptosar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is CAMPTOSAR used for?

"Camptosar Injection is a medication that is used to treat cancer of the colon and rectum. It is typically given with other cancer medications in a combination chemotherapy treatment."

Answered by AI

Is CAMPTOSAR a chemo drug?

"Camptosar is a chemotherapy drug that kills cancer cells. Camptosar is made from plants and inhibits topoisomerase I."

Answered by AI

Does CAMPTOSAR cause hair loss?

"It may be replaced by much thinner hair. You may lose all or most of your eyelashes and eyebrows

It is fairly common to lose hair while taking Irinotecan. This typically starts 3-4 weeks after the first dose, but can happen sooner. All or most of the hair on the head, as well as the eyelashes and eyebrows, may fall out. It may be replaced by much thinner hair."

Answered by AI

How effective is CAMPTOSAR?

"Of patients who had stopped responding to both taxanes and anthracyclines, the overall anti-cancer response rate following weekly Camptosar was 27%. Of patients who had stopped responding to either taxanes or anthracyclines, the anti-cancer response rates following Camptosar were approximately 18%."

Answered by AI

Clinical Trials for Camptosar

Have you considered Camptosar clinical trials? We made a collection of clinical trials featuring Camptosar, we think they might fit your search criteria.
Have you considered Camptosar clinical trials? We made a collection of clinical trials featuring Camptosar, we think they might fit your search criteria.
Have you considered Camptosar clinical trials? We made a collection of clinical trials featuring Camptosar, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top